{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:25:42Z","timestamp":1792743942071,"version":"4.5.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032702","name":"Genmab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>AXL, a receptor tyrosine kinase related to oncogenic processes, is aberrantly expressed in various cancers and associated with treatment resistance. Enapotamab vedotin (EnaV), a novel anti-AXL human IgG1 and monomethyl auristatin E antibody\u2013drug conjugate, demonstrated antitumor activity in preclinical models, including non\u2013small cell lung cancer (NSCLC). This phase 1\/2 study assessed the safety and preliminary efficacy of EnaV in solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This study comprised dose-escalation and dose-expansion phases; both phases investigated EnaV once every 3 weeks (Q3W) and EnaV on days 1, 8, and 15 of a 28-day cycle (3Q4W). Primary objectives determined the maximum tolerated dose (dose escalation) and safety (dose expansion). Pharmacokinetic profile, antitumor activity, and AXL expression were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>During dose escalation, 32 patients received EnaV Q3W; 15 received EnaV 3Q4W. The maximum tolerated dose and recommended phase 2 dose were 2.2 mg\/kg in Q3W and 1.0 mg\/kg in 3Q4W schedules. In dose expansion, 189 patients received EnaV Q3W; 70 received EnaV 3Q4W. Common adverse events in dose expansion included fatigue, constipation, nausea, decreased appetite, and diarrhea. Overall response rates ranged from 4.5% to 12.5% with Q3W dose schedule and from 9.1% to 11.5% with 3Q4W dose schedule. Disease control rates for NSCLC cohorts were 40.9% to 50.0%. NSCLC subset analysis demonstrated correlation between radiomics signature and disease control. The relationship between clinical activity and AXL expression was not apparent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>EnaV had an acceptable safety profile; however, because the evaluation of antitumor activity did not show clinically meaningful responses, clinical development of EnaV was discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>EnaV, an anti-AXL human IgG1 and monomethyl auristatin E antibody\u2013drug conjugate, showed single-agent antitumor activity in preclinical models. This phase 1\/2 study of EnaV demonstrated a manageable safety profile and antitumor activity in selected tumor types. Further studies exploring alternative targeting modalities, patient selection, and\/or combinations are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0359","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:50:51Z","timestamp":1761846651000},"page":"2066-2078","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase I\/II Study of AXL-Specific Antibody\u2013Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-9003","authenticated-orcid":false,"given":"Kristoffer Staal","family":"Rohrberg","sequence":"first","affiliation":[{"name":"1Department of Oncology, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8321-4212","authenticated-orcid":false,"given":"Juanita S.","family":"Lopez","sequence":"additional","affiliation":[{"name":"2Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-6824","authenticated-orcid":false,"given":"Mohammed M.","family":"Milhem","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-5846","authenticated-orcid":false,"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[{"name":"4Division of Molecular Oncology and Immunology, Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands."},{"name":"5Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, the Netherlands."},{"name":"6Department of Hematology and Oncology, University Clinic Regensburg (UKR), Regensburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7103-3219","authenticated-orcid":false,"given":"Irene","family":"Reijers","sequence":"additional","affiliation":[{"name":"4Division of Molecular Oncology and Immunology, Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7008","authenticated-orcid":false,"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[{"name":"7The Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-1444","authenticated-orcid":false,"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[{"name":"8Newcastle University, Newcastle upon Tyne, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-1660","authenticated-orcid":false,"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"9Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7821-4928","authenticated-orcid":false,"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[{"name":"10Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-5716","authenticated-orcid":false,"given":"Elaine","family":"Shum","sequence":"additional","affiliation":[{"name":"11Medical Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6545-2927","authenticated-orcid":false,"given":"Heather M.","family":"Shaw","sequence":"additional","affiliation":[{"name":"12National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Clinical Research Facility, National Health Service (NHS) Foundation Trust, London, United Kingdom."},{"name":"13Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-9697","authenticated-orcid":false,"given":"Philip R.","family":"Debruyne","sequence":"additional","affiliation":[{"name":"14Department of Medical Oncology, Kortrijk Cancer Centre, AZ Groeninge, Kortrijk, Belgium."},{"name":"15Medical Technology Research Centre (MTRC), School of Allied Health and Social Care, Faculty of Health, Medicine and Social Care, Anglia Ruskin University, Chelmsford, United Kingdom."},{"name":"16School of Nursing and Midwifery, Faculty of Health, University of Plymouth, Plymouth, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5952-7267","authenticated-orcid":false,"given":"Cristopher","family":"Lao","sequence":"additional","affiliation":[{"name":"17Division of Hematology Oncology, Department of Internal Medicine, Rogel Cancer Center, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-4600","authenticated-orcid":false,"given":"Jean-Francois","family":"Baurain","sequence":"additional","affiliation":[{"name":"18Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, UC Louvain and Institute for Experimental and Clinical Research, Universit\u00e9 Catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-0235","authenticated-orcid":false,"given":"Jennifer H.","family":"Choe","sequence":"additional","affiliation":[{"name":"19Division of Hematology and Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7390-0761","authenticated-orcid":false,"given":"Eelke","family":"Gort","sequence":"additional","affiliation":[{"name":"20Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-2658","authenticated-orcid":false,"given":"Yujie","family":"Zhao","sequence":"additional","affiliation":[{"name":"21Department of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-0043","authenticated-orcid":false,"given":"Guy","family":"Jerusalem","sequence":"additional","affiliation":[{"name":"22Medical Oncology Department, CHU Li\u00e8ge and Li\u00e8ge University, Liege, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[{"name":"23General Medical Oncology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7781-1109","authenticated-orcid":false,"given":"Andrew William","family":"Chen","sequence":"additional","affiliation":[{"name":"24Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"25Department of Radiology, Columbia University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5067-8835","authenticated-orcid":false,"given":"Eric A.","family":"Cohen","sequence":"additional","affiliation":[{"name":"24Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"25Department of Radiology, Columbia University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-6592","authenticated-orcid":false,"given":"Walter C.","family":"Mankowski","sequence":"additional","affiliation":[{"name":"24Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"25Department of Radiology, Columbia University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-8835","authenticated-orcid":false,"given":"Leonid","family":"Roshkovan","sequence":"additional","affiliation":[{"name":"24Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-2291","authenticated-orcid":false,"given":"Sharyn I.","family":"Katz","sequence":"additional","affiliation":[{"name":"24Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9031-5126","authenticated-orcid":false,"given":"Despina","family":"Kontos","sequence":"additional","affiliation":[{"name":"24Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"25Department of Radiology, Columbia University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3012-8509","authenticated-orcid":false,"given":"Lauren K.","family":"Brady","sequence":"additional","affiliation":[{"name":"26Genmab US., Plainsboro, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-2872","authenticated-orcid":false,"given":"Mohammed","family":"Qutaish","sequence":"additional","affiliation":[{"name":"26Genmab US., Plainsboro, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6618-0479","authenticated-orcid":false,"given":"Patricia Garrido","family":"Castro","sequence":"additional","affiliation":[{"name":"27Genmab B.V., Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4689-1218","authenticated-orcid":false,"given":"Nora","family":"Pencheva","sequence":"additional","affiliation":[{"name":"27Genmab B.V., Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-4659","authenticated-orcid":false,"given":"Gaurav","family":"Bajaj","sequence":"additional","affiliation":[{"name":"26Genmab US., Plainsboro, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3115-5578","authenticated-orcid":false,"given":"Yali","family":"Fu","sequence":"additional","affiliation":[{"name":"26Genmab US., Plainsboro, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3313-3923","authenticated-orcid":false,"given":"Kristian","family":"Windfeld","sequence":"additional","affiliation":[{"name":"28Genmab A\/S, Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5597-1252","authenticated-orcid":false,"given":"Panagiota","family":"Reiter","sequence":"additional","affiliation":[{"name":"28Genmab A\/S, Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-1934","authenticated-orcid":false,"given":"Maria","family":"Jure-Kunkel","sequence":"additional","affiliation":[{"name":"26Genmab US., Plainsboro, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2951-0245","authenticated-orcid":false,"given":"Brandon W.","family":"Higgs","sequence":"additional","affiliation":[{"name":"26Genmab US., Plainsboro, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7254-5977","authenticated-orcid":false,"given":"Katayoun I.","family":"Amiri","sequence":"additional","affiliation":[{"name":"26Genmab US., Plainsboro, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5031-3792","authenticated-orcid":false,"given":"Tahamtan","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"26Genmab US., Plainsboro, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2534-675X","authenticated-orcid":false,"given":"Ulf","family":"Forssmann","sequence":"additional","affiliation":[{"name":"28Genmab A\/S, Copenhagen, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":false,"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"29Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[{"name":"30Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2025112602215754200_bib1","doi-asserted-by":"crossref","first-page":"811247","DOI":"10.3389\/fonc.2022.811247","article-title":"The development of AXL inhibitors in lung cancer: recent progress and challenges","volume":"12","author":"Sang","year":"2022","journal-title":"Front Oncol"},{"key":"2025112602215754200_bib2","first-page":"67","article-title":"Targeting AXL in NSCLC","volume":"12","author":"Zaman","year":"2021","journal-title":"Lung Cancer (Auckl)"},{"key":"2025112602215754200_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/tcmj.tcmj_129_20","article-title":"Dual targeting of TAM receptors Tyro3, Axl, and MerTK: role in tumors and the tumor immune microenvironment","volume":"33","author":"Wang","year":"2021","journal-title":"Tzu Chi Med J"},{"key":"2025112602215754200_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025112602215754200_bib5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"2025112602215754200_bib6","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1038\/ncomms13898","article-title":"Reprogramming the immunological microenvironment through radiation and targeting Axl","volume":"7","author":"Aguilera","year":"2016","journal-title":"Nat Commun"},{"key":"2025112602215754200_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"2025112602215754200_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.7150\/thno.15083","article-title":"Gas6\/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt\/GSK-3\u03b2\/\u03b2-catenin signaling","volume":"6","author":"Wang","year":"2016","journal-title":"Theranostics"},{"key":"2025112602215754200_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.canlet.2016.08.022","article-title":"Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer","volume":"382","author":"Hu","year":"2016","journal-title":"Cancer Lett"},{"key":"2025112602215754200_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025112602215754200_bib11","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025112602215754200_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112602215754200_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025112602215754200_bib14","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025112602215754200_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat Med"},{"key":"2025112602215754200_bib16","doi-asserted-by":"crossref","first-page":"e128199","DOI":"10.1172\/jci.insight.128199","article-title":"Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer","volume":"4","author":"Koopman","year":"2019","journal-title":"JCI Insight"},{"key":"2025112602215754200_bib17","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.3390\/ijms23147493","article-title":"Enapotamab vedotin, an AXL-specific antibody-drug conjugate, demonstrates antitumor efficacy in patient-derived xenograft models of soft tissue sarcoma","volume":"23","author":"Van Renterghem","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025112602215754200_bib18","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","article-title":"Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade","volume":"81","author":"Boshuizen","year":"2021","journal-title":"Cancer Res"},{"key":"2025112602215754200_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 7","key":"2025112602215754200_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2019.37.7_suppl.377","article-title":"Mature results from EV-101: a phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC)","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025112602215754200_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ebiom.2018.02.001","article-title":"Common co-activation of AXL and CDCP1 in EGFR-mutation-positive non-smallcell lung cancer associated with poor prognosis","volume":"29","author":"Karachaliou","year":"2018","journal-title":"EBioMedicine"},{"key":"2025112602215754200_bib22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","article-title":"User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability","volume":"31","author":"Yushkevich","year":"2006","journal-title":"Neuroimage"},{"key":"2025112602215754200_bib23","first-page":"011018","article-title":"Cancer imaging phenomics toolkit: quantitative imaging analytics for precision diagnostics and predictive modeling of clinical outcome","volume":"5","author":"Davatzikos","year":"2018","journal-title":"J Med Imaging (Bellingham)"},{"key":"2025112602215754200_bib24","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41598-022-08412-9","article-title":"Generalized ComBat harmonization methods for radiomic features with multi-modal distributions and multiple batch effects","volume":"12","author":"Horng","year":"2022","journal-title":"Sci Rep"},{"key":"2025112602215754200_bib25","doi-asserted-by":"crossref","first-page":"ra97","DOI":"10.1126\/scisignal.aaf8175","article-title":"The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer","volume":"9","author":"Antony","year":"2016","journal-title":"Sci Signal"},{"key":"2025112602215754200_bib26","doi-asserted-by":"crossref","first-page":"640863","DOI":"10.3389\/fonc.2021.640863","article-title":"The role of microtubules in pancreatic cancer: therapeutic progress","volume":"11","author":"Albahde","year":"2021","journal-title":"Front Oncol"},{"key":"2025112602215754200_bib27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.20892\/j.issn.2095-3941.2019.0252","article-title":"The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview","volume":"16","author":"Qui\u00f1onero","year":"2019","journal-title":"Cancer Biol Med"},{"key":"2025112602215754200_bib28","doi-asserted-by":"crossref","first-page":"15118","DOI":"10.1038\/s41598-021-94558-x","article-title":"Nationwide case-control study of risk factors and outcomes for community-acquired sepsis","volume":"11","author":"Lindstr\u00f6m","year":"2021","journal-title":"Sci Rep"},{"key":"2025112602215754200_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112602215754200_bib30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112602215754200_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"2025112602215754200_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann Oncol"},{"key":"2025112602215754200_bib33","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1200\/JCO.23.02166","article-title":"CONTACT-01: a randomized phase III trial of atezolizumab + cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025112602215754200_bib34","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-06-1941","article-title":"Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors","volume":"13","author":"Kyle","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2025112602215754200_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 16","key":"2025112602215754200_bib36","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/JCO.2023.41.16_suppl.1082","article-title":"Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+\/HER2\u2212 metastatic breast cancer (mBC): biomarker results from the phase 3 TROPiCS-02 study","volume":"41","author":"Bardia","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025112602215754200_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"key":"2025112602215754200_bib38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-21-0715","article-title":"Preclinical development of ADCT-601, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting AXL-expressing cancers","volume":"21","author":"Zammarchi","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2025112602215754200_bib39","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1158\/1078-0432.CCR-21-4148","article-title":"Novel radiomic measurements of tumor-associated vasculature morphology on clinical imaging as a biomarker of treatment response in multiple cancers","volume":"28","author":"Braman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025112602215754200_bib40","doi-asserted-by":"crossref","first-page":"eabq4609","DOI":"10.1126\/sciadv.abq4609","article-title":"A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors","volume":"8","author":"Alilou","year":"2022","journal-title":"Sci Adv"},{"key":"2025112602215754200_bib41","doi-asserted-by":"crossref","first-page":"15290","DOI":"10.1038\/s41598-018-33473-0","article-title":"Quantitative vessel tortuosity: a potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas","volume":"8","author":"Alilou","year":"2018","journal-title":"Sci Rep"},{"key":"2025112602215754200_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13058-022-01516-0","article-title":"Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment","volume":"24","author":"Wang","year":"2022","journal-title":"Breast Cancer Res"},{"key":"2025112602215754200_bib43","doi-asserted-by":"crossref","first-page":"eadf0837","DOI":"10.1126\/sciadv.adf0837","article-title":"Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets","volume":"9","author":"Su","year":"2023","journal-title":"Sci Adv"},{"key":"2025112602215754200_bib44","doi-asserted-by":"crossref","first-page":"869676","DOI":"10.3389\/fimmu.2022.869676","article-title":"Dissecting the role of AXL in cancer immune escape and resistance to immune checkpoint inhibition","volume":"13","author":"Engelsen","year":"2022","journal-title":"Front Immunol"},{"key":"2025112602215754200_bib45","doi-asserted-by":"crossref","first-page":"102639","DOI":"10.1016\/j.ctrv.2023.102639","article-title":"AXL - a new player in resistance to HER2 blockade","volume":"121","author":"Adam-Artigues","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2025112602215754200_bib46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2017.05.007","article-title":"First-in-human phase I study of oral S49076, a unique MET\/AXL\/FGFR inhibitor, in advanced solid tumours","volume":"81","author":"Rodon","year":"2017","journal-title":"Eur J Cancer"},{"issue":"Suppl 15","key":"2025112602215754200_bib47","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.1200\/JCO.2019.37.15_suppl.9098","article-title":"A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy","volume":"37","author":"Felip","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025112602215754200_bib48","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41416-025-03090-6","article-title":"A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients","volume":"133","author":"Sooi","year":"2025","journal-title":"Br J Cancer"},{"issue":"Suppl 16","key":"2025112602215754200_bib49","doi-asserted-by":"crossref","first-page":"e15010","DOI":"10.1200\/JCO.2023.41.16_suppl.e15010","article-title":"Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors","volume":"41","author":"Shen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2025112602215754200_bib50","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.esmoop.2024.102443","article-title":"53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma","volume":"9","author":"Pollack","year":"2024","journal-title":"ESMO Open"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0359\/3667740\/crc-25-0359.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/2066\/3696592\/crc-25-0359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/2066\/3696592\/crc-25-0359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:22:06Z","timestamp":1764141726000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/11\/2066\/769323\/Phase-I-II-Study-of-AXL-Specific-Antibody-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0359","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30719280","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719271","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719262","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719250","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719283","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719253","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719286","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719274","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719244","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719277","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719265","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719268","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719256","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719289","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719259","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30719247","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8169432","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}